Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585558 | 1.00 | ALDH1A1 (0.36) | ALDH1A1PDGFRBPDGFRAADORA1TP53 | |
| SCHEMBL2587912 | 0.87 | ALDH1A1 (0.34) | ALDH1A1PDGFRBPDGFRAADORA1TP53 | |
| SCHEMBL2587909 | 0.87 | ALDH1A1 (0.34) | ALDH1A1PDGFRBPDGFRAADORA1TP53 | |
| SCHEMBL2576714 | 0.84 | EPHX2 (0.35) | ALDH1A1PDGFRBPDGFRAADORA1TP53 | |
| SCHEMBL2582589 | 0.84 | SMN1; SMN2 (0.36) | ALDH1A1ADORA1TP53SMN1; SMN2BRD4 | |
| SCHEMBL2576717 | 0.84 | EPHX2 (0.35) | ALDH1A1PDGFRBPDGFRAADORA1TP53 | |
| SCHEMBL2582584 | 0.84 | SMN1; SMN2 (0.36) | ALDH1A1ADORA1TP53SMN1; SMN2BRD4 | |
| SCHEMBL2590550 | 0.81 | SMYD3 (0.33) | ALDH1A1ADORA1BRD4MEN1KMT2A | |
| SCHEMBL2541849 | 0.74 | HTR2A (0.52) | — | |
| SCHEMBL2540454 | 0.74 | DRD2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569319-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| EP-2569319-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8513238-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513238-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513238-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2569319-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141396-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141396-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275801-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | ALDH1A1 564/4885PDGFRB 421/4885PDGFRA 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.